As an emerging private biotechnology company, Adnexus Therapeutics Inc faces not only the pressure from those established big companies but also obstacles in gathering enough fund. Based on such situation, Dr. John Mendlein strongly recommended that the company find a partner with sufficient monetary and expertise resources. That’s where BMS appeared, showing great interest in ATI’s invention and the cooperation programme.
Now the ATI achieved great progress and the future seems promising. BMS becomes more and more serious about purchasing the company’s outright. However, whether to keep the collaborative partnership or to pursuit independent development is hard for ATI to decide. What’s more, the next emphasis on Angiocept or Adnectins reamins unknown. This paper will mainly focuses on analyzing the advantages and disadvantages of this small company, while making comparison between the two main products.
Secondly, the paper will make SWOT analysis and finally come to a conclusion on ATI future development. About ATI ATI (used to be CTI) was led by a technology officer who intended to develop biologics drug in a venture setting. At the first stage the company experienced a tough time while confronting with technical challenges and impatient investors. But soon problems were relieved, since the company purchased two key products from a bankruptcy company. Great progress took place in ATI after the series purchases.
Therefore, the new CEO was managed to find a good partner with whom ATI could commercialize its drug. Though faced many challenges from technology and management, ATI set up its cooperation with BMS at last. About Adnectins and Angiocept Adnectins came up as a solution to the technological problem faced by ATI, while Angiocept derived from the deep research as a trail drug for cancer cure. SWOT Analysis Strength 1. Breakthrough in pharmacology with promising drugs 2. Initial permission from FDA.
3. Sufficient resources in fund and knowledge 4. Profound protection of intellectual property and few possibility of getting involved into patent issues. Weakness 1. Uncertainty in drug development 2. Lacking experience in commercialization 3. Lacking independence 4. Opportunity 1. Potential market in the new drugs 2. Threat 1. Pressure from established companies 2. Unsteady stream of cash 3. Rapid-pace development in biotechnology results in uncertainty in small company development.